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For treatment of patients with rheuma-
toid arthritis, drugs and biologicals are
now available which are not primarily
analgesics or anti-inflammatory agents
but which have the capacity to prevent or
slow structural damage in the rheuma-
toid joint (eg methotrexate, leflunomide,
etanercept, infliximab). Similarly, in
animal models of osteoarthritis (OA),
pharmacological and biological agents
have been identified whose primary
action is not the reduction of joint pain
or inflammation (as with first-line
therapy), but which can prevent struc-
tural damage in a joint at high risk for
developing OA and/or slow the progres-
sion of tissue damage in a joint in which
OA is already established. Such agents,
which are viewed as potential second-
line therapy for OA, have been desig-
nated disease-modifying OA drugs
(DMOADs)1. To date, none of these
agents has been convincingly shown to
have disease-modifying activity in
humans with OA.
Disease-modifying osteoarthritis
drugs
Most DMOADs decrease articular carti-
lage levels of matrix metalloproteinases
(MMPs) (eg collagenase, gelatinase,
stromelysin) which have been implicated
in damage of the cartilage in OA. Some
DMOADs have broad specificity against
MMPs, while others have relatively high
specificity against one MMP2.
Doxycycline
Doxycycline, the DMOAD effect of
which we are currently evaluating in a
placebo-controlled clinical trial, initially
generated interest as a possible DMOAD
when it was shown to inhibit in vitro the
92 kDa gelatinase which degrades type
XI collagen in articular cartilage, and
that this inhibition could be reversed by
addition of small amounts of the divalent
cations, calcium or zinc3. These observa-
tions led to in vivo studies in canine
cruciate-deficiency models of OA, in
which doxycycline was shown to possess
DMOAD activity regardless of whether it
was administered prophylactically (ie
promptly after the induction of joint
instability)4 or therapeutically (ie after
joint damage has already been estab-
lished)5. Evidence supporting these
observations was subsequently obtained
with other animal models of OA6,7 and
with chemically modified tetracyclines.
The initial impression was that doxy-
cycline exerted its effect through
chelation either of the calcium atoms
which are essential for the molecular
stability of MMPs or of the zinc atom
which is present at the active site of these
enzymes. This could not, however,
explain the observation that striking
reductions were observed not only in
levels of the active MMPs, but also in the
levels of total MMP in the cartilage after
administration of doxycycline in animal
models of OA4 or to humans with the
disease8. Further work aimed at eluci-
dating the underlying mechanism of
action has indicated that doxycycline
may inhibit transcription of mRNA
involved in MMP synthesis9 and of
mRNA for inducible nitric oxide
synthase (iNOS)10 – an enzyme whose
action results in the generation within
cartilage of nitric oxide, a powerful
stimulant of the production and release
of MMPs by chondrocytes11. Other work
has shown that doxycycline may inhibit
the translation of MMPs12.
Anthraquinones
There is also interest currently in the
anthraquinone, diacerhein, as a potential
DMOAD. This drug has been shown to
slow the development of chondropathy
in a canine cruciate-deficiency model13.
In support of these data, a placebo-
controlled clinical trial of diacerhein in
humans with hip OA has suggested a
significant DMOAD effect in those who
completed the three-year period of
treatment14.
Glucosamine
Glucosamine sulphate slows the progres-
sion of joint damage in patients with
knee OA, as reflected by changes in the
rate of narrowing of the joint space of the
medial tibiofemoral compartment in
standing knee radiographs15,16. However,
because the patients treated with gluco-
samine reported a decrease in joint pain
in comparison with those who received
placebo, it is possible that an increase in
knee extension associated with the
decrease in pain may itself increase the
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interbone distance on the radiograph
without necessarily affecting the
thickness of the articular cartilage.
Furthermore, concerns have been
expressed about the reproducibility of
positioning of the joint when conven-
tional standing knee radiographs are
used in OA progression studies (as in the
clinical trials of glucosamine), raising
questions about the adequacy of sample
sizes in such studies.
Side effects of matrix
metalloproteinase inhibition
Although the above developments are
encouraging, there is concern about
potential side effects of MMP inhibition.
Reports of the development of cancer in
some subjects who were treated with an
MMP inhibitor and of an increase in
fibrosis in others treated with a different
MMP inhibitor have tempered the
enthusiasm of some pharmaceutical
companies for DMOAD development.
In addition, it is by no means clear that
demonstration of a pharmacologically or
biologically mediated chondroprotective
effect will be accompanied by improve-
ment in joint pain, a decrease in
disability or a reduction in the need for
costly total joint arthroplasty.
Evaluation of disease-modifying
osteoarthritis drugs
Uncertainty also exists with regard to the
outcome measures required to evaluate a
DMOAD effect. While magnetic
resonance imaging (MRI) has great
sensitivity, it has not been validated as an
outcome measure in OA clinical trials.
Conventional radiography is relatively
inexpensive and easily performed, but it
has significant limitations because of the
lack of reliability of the procedure17.
Newer radiographic approaches aim to
provide reproducible radioanatomical
positioning of the joint by employing
fluoroscopy18 which, however, increases
costs, may present logistic barriers (eg
an elective knee radiograph competing
with an emergency MRI of the head in
the clinical radiology department), and
results in some radiation exposure of the
subject. Efforts to standardise the
positioning of the knee by non-
fluoroscopic methods are now receiving
attention19,20, but their reliability in
clinical trials has yet to be established.
Conclusions
The great gains achieved recently in our
understanding of the pathobiology and
pathobiochemistry of cartilage damage
in OA have led to efforts within the
pharmaceutical industry and in
academia to develop agents which
inhibit cartilage MMPs. It remains to be
seen whether any of these will prove to
be clinically useful DMOADs. Even if
this should prove to be the case, it is
uncertain whether DMOADs will have a
beneficial effect on symptoms or
disability. The correlation between
progression of radiographic changes of
OA and progression of joint pain and
disability is not strong21.
Given the understandable interest in
the development of second-line drug
therapy for OA, it should be noted that
current first-line therapy leaves much to
be desired. The recent availability of
coxibs (COX-1 sparing non-steroidal
anti-inflammatory drugs (NSAIDs))
may significantly decrease the risk of a
serious upper gastrointestinal adverse
event (eg ulcer, haemorrhage, obstruc-
tion, perforation). However, these drugs
are no more effective than non-opioid
analgesics such as paracetamol or
NSAIDs22, and have similar adverse
effects on renal function, fluid retention,
blood pressure elevation, precipitation
of congestive heart failure, etc23.
Additionally, the magnitude of improve-
ment in joint pain achieved today with
first-line agents is only modest. Based on
measurements on visual analogue scales,
improvement in joint pain with the
currently available agents is only
20–25%, while that with placebo may be
15%24–27. This may account for the
observation that only about 15% of
patients with OA who were started on an
NSAID were still taking the same NSAID
12 months later28. While efforts to
develop DMOADs are laudable, more
effective and safer first-line drugs for OA
are needed. This need should not be
ignored.
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